Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alpha Ject LiVac SRS
- Development stage
- Unknown
- Lead developer
- PHARMAQ
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Injection
01
Overview
Alpha Ject LiVac SRS is a live attenuated vaccine developed for the aquaculture industry to protect salmonid fish against Salmonid Rickettsial Septicaemia (SRS), also known as Piscirickettsiosis. The vaccine contains a modified, non-pathogenic strain of the intracellular bacterium *Piscirickettsia salmonis*. Developed by PHARMAQ (a subsidiary of Zoetis), it is designed to stimulate a robust and long-lasting immune response in Atlantic salmon, Coho salmon, and rainbow trout. It represents a significant technological shift from traditional inactivated whole-cell bacterin vaccines, offering improved efficacy in reducing mortalities in the Chilean salmon farming industry, where SRS is the most economically damaging disease. The vaccine is administered via injection and its performance is known to be temperature-dependent during the immunization period.
- Brand names
- Alpha Ject LiVac SRS
- Other names
- LiVac SRS
02
Targets
Piscirickettsia salmonis
Beyond the preview
Go deeper on Alpha Ject LiVac SRS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alpha Ject LiVac SRS.